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Abstract
Background: Recently, the IMPRES study revealed that systemic imatinib improves exercise capacity in patients
with advanced pulmonary arterial hypertension. Imatinib blocks the tyrosine kinase activity of the platelet-derived
growth factor (PDGF)-receptor (PDGFR), acts antiproliferative and relaxes pulmonary arteries. However so far, the
relaxant effects of imatinib on pulmonary veins (PVs) and on the postcapillary resistance are unknown, although
pulmonary hypertension (PH) due to left heart disease (LHD) is most common and primarily affects PVs. Next, it is
unknown whether activation of PDGFR alters the pulmonary venous tone. Due to the reported adverse effects of
systemic imatinib, we evaluated the effects of nebulized imatinib on the postcapillary resistance.
Methods: Precision-cut lung slices (PCLS) were prepared from guinea pigs. PVs were pre-constricted with Endothelin-1
(ET-1) and the imatinib-induced relaxation was studied by videomicroscopy; PDGF-BB-related vascular properties were
evaluated as well. The effects of perfused/nebulized imatinib on the postcapillary resistance were studied in cavine
isolated perfused lungs (IPL). Intracellular cAMP/cGMP was measured by ELISA in PVs.
Results: In PCLS, imatinib (100 μM) relaxed pre-constricted PVs (126%). In PVs, imatinib increased cAMP, but not cGMP
and inhibition of adenyl cyclase or protein kinase A reduced the imatinib-induced relaxation. Further, inhibition
of KATP-channels, BKCa2þ -channels or Kv-channels diminished the imatinib-induced relaxation, whereas inhibition
of NO-signaling was without effect. In the IPL, perfusion or nebulization of imatinib reduced the ET-1-induced
increase of the postcapillary resistance. In PCLS, PDGF-BB contracted PVs, which was blocked by imatinib and by
the PDGFR-β kinase inhibitor SU6668, whereas inhibition of PDGFR-α (ponatinib) had no significant effect.
Conversely, PDGFR-β kinase inhibitors (SU6668/DMPQ) relaxed PVs pre-constricted with ET-1 comparable to
imatinib, whereas the PDGFR-α kinase inhibitor ponatinib did not.
Conclusions: Imatinib-induced relaxation depends on cAMP and on the activation of K+-channels. Perfused or
nebulized imatinib significantly reduces the postcapillary resistance in the pre-constricted (ET-1) pulmonary venous bed.
Hence, nebulization of imatinib is feasible and might reduce systemic side effects. Conversely, PDGF-BB contracts PVs
by activation of PDGFR-β suggesting that imatinib-induced relaxation depends on PDGFR-β-antagonism. Imatinib
combines short-term relaxant and long-term antiproliferative effects. Thus, imatinib might be a promising therapy for
PH due to LHD.
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Background
Pulmonary hypertension (PH) due to left heart disease
(LHD) is the most common cause of PH [1–5]. In re-
sponse to elevated left ventricular (LV) or atrial filling
pressure, PH due to LHD is associated with increased
pulmonary capillary wedge pressure (Ppcw) >15 mmHg
leading by backwards transmission to elevated pulmon-
ary arterial pressure (PPA) ≥25 mmHg, even though the
transpulmonary gradient (TPG) often remains ≤12 mmHg
[6]. Though, some patients develop severe PH character-
ized by a TPG ≥12, by proliferative pulmonary vascular
disease and elevated pulmonary vascular resistance (PVR)
[6]. PH due to LHD primarily affects the pulmonary veins
(PVs) [7], thus it is also called postcapillary PH or pulmon-
ary venous hypertension (PVH) [1, 4, 8]. This feature is
pivotal for the therapy of PH due to LHD, as vasodilators
acting primarily in the pulmonary arterial bed may in-
crease pulmonary perfusion leading to elevated hydrostatic
pressure, pulmonary edema and elevated PVR [8]. Until
now, specific agents to treat PH due to LHD are missing,
although some agents, e.g. the PDE-III inhibitor milrinone
exert relaxant effects in human PVs [9]. Thus, current
guidelines recommend the management of the underlying
condition, e.g. the therapy of LHD, the repair of valvular
heart disease or LV-assist device implantation [3, 6].
However, cardiac surgery is at high risk. Therefore, new
therapeutic approaches are warranted.
The tyrosine kinase inhibitor (TKI) imatinib represents
such a novel approach which demonstrated already
promise in experimental models [10] and clinical trials
[11–13]. Moreover, two studies in rats show that ima-
tinib may act also as a vasodilator in rat pulmonary ar-
teries (PAs) and aortas [14, 15]. Recently, the IMPRES
study showed that oral imatinib improves exercise
capacity and hemodynamics in patients with advanced
pulmonary arterial hypertension (PAH) [16]. So far, al-
though relevant, the effects of imatinib have been
never studied in the pulmonary venous bed or in PH
due to LHD. Of note, the IMPRES study uncovered
also severe imatinib-related adverse effects such as
subdural hematoma or QTc prolongation [16, 17].
Thus, a local application, e.g. by nebulization could be
advantageous to improve the safety of imatinib [18].
Imatinib resembles an intriguing approach in PH, as it
targets the vascular remodeling, a major pathophysiologic
condition of PH. It inhibits the receptor tyrosine kinase
(RTK) platelet derived growth factor (PDGF)-receptor
(PDGFR) and counteracts thereby PDGF [19, 20]. Both
PDGF and its receptor are overexpressed in pulmonary
arterial smooth muscle cells (SMCs) and to lesser ex-
tent in endothelial cells of patients with idiopathic PAH
[21]. Further, PDGFR-β immunoreactivity is increased
in small arterioles and venules, as well as in capillaries
of patients with pulmonary venous occlusive disease
and systemic sclerosis associated PAH [22]. PDGFR
consists of two subunits (αα, αβ, ββ) among which
PDGFR-β mediates proliferation [23]. At present it is
not known whether PDGF alters the pulmonary vascu-
lar tone. In systemic vessels, PDGF acts as a vasodilator
in mesenteric arteries [24, 25] and as a vasoconstrictor
in aortas [26]. However, these discrepant findings do
not allow to predict the action of PDGF in the lungs, in
particular, because the pulmonary and the systemic vas-
culature are remarkably dissimilar [27].
With regard to PH due to LHD, there are several
unsolved issues concerning the effects of imatinib and
PDGF on the pulmonary venous tone. 1) Does imatinib
relax PVs? 2) Which are the possible underlying mecha-
nisms? 3) Does imatinib affect the postcapillary resist-
ance (Rpost)? 4) Does imatinib exert pulmonary relaxant
effects when applied by nebulization? 5) Does PDGF act
as a pulmonary vasoconstrictor? — A finding that would
in part explain the relaxant effects of imatinib. In the
present study, we address these questions to evaluate the
value of imatinib within the context of PH due LHD.
Methods
Animals
Female Dunkin Hartley GPs (350 ± 50 g) were pur-
chased from Charles River (Sulzfeld, Germany). Animal
studies were approved by the Landesamt für Natur,
Umwelt und Verbraucherschutz Nordrhein-Westfalen
(ID: 8.87-51.05.20.10.245) and performed following the
Directive 2010/63/EU of the European Parliament.
PCLS
PCLS were prepared as described [28, 29]. Briefly, intra-
peritoneal anesthesia was performed with 95 mg kg−1
pentobarbital (Narcoren; Garbsen, Germany) and veri-
fied by missing reflexes. The GP was bled, the trachea
cannulated and the diaphragm opened. The lungs were
filled via the trachea with 1.5% low melting agarose. To
harden the lungs, they were cooled with ice. Then, tissue
cores (diameter 11 mm) were prepared and cut into about
300 μM thick slices with a Krumdieck tissue slicer
(Alabama Research & Development, Munford, AL, USA).
PCLS were incubated at 37 °C and repeated medium
changes were performed to wash out the agarose.
Cyclic AMP and cGMP enzyme immunoassay
To analyze cAMP/cGMP, PVs were isolated out of tissue
cores guided by their anatomical landmarks, e.g. the PAs
accompany the airways, whereas PV lies aside. PVs were
incubated in medium, flushed with imatinib (100 μM)
and after 30 min frozen by liquid nitrogen. Cyclic AMP/
cGMP was quantified with ELISA-kits following the
manufacturer’s protocol. For stabilization, all samples
or standards were acetylated. To measure cAMP, all
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samples were diluted 1:2 with 0.1 M HCL. The ELISA
was evaluated at 405 nM (GENIOS, Tecan, Switzerland).
Measurements, pharmacological interventions and
videomicroscopy
To study the relaxant effects of imatinib, PVs were in-
cubated with 1 nM ET-1 (Fig. 1b) to induce a stable
contraction after 1 h. If a signaling pathway was evalu-
ated, PCLS were additionally pre-treated for 1 h with
one of the following inhibitors at concentrations about
10–100 fold above the IC50 value of the target: Adenyl
cyclase: 100 μM SQ22536 (IC50: 1.4 – 200 μM) [30];
protein kinase A (PKA): 1 μM KT5720 (IC50: 60 nM); NO-
synthase: 100 μM L-NAME (IC50: 25 μM); protein kinase
G (PKG): 2 μM KT5823 (IC50: 0.23 μM); KATP-channel:
10 μM glibenclamide (IC50: 20 – 200 nM); BKCa
2+-channel:
100 nM iberiotoxin (IC50: 10 nM); Kv-channel: 5 mM 4-
aminopyridine (IC50: 0.3 – 1.1 mM) [31]; PDGFR-α: 100
nM ponatinib (IC50: 1.1 nM) [32–34]; PDGFR-β: 5 μM
SU6668 (IC50: 0.008 – 0.1 μM) [35–37] or 5 μM DMPQ
(IC50: 0.08 μM). Subsequently, concentration-response
curves with imatinib, ponatinib, SU6668 or DMPQ were
performed. To study the contractile effect of PDGF-BB,
PVs were pretreated with 100 μM imatinib (PDGFR); 5 μM
SU6668 (PDGFR-β) or 100 nM ponatinib (PDGFR-α). In
PCLS, all changes of the initial vessel area (IVA) were
quantified in % and are reported as “Change [% of IVA]”.
Hence, a vessel area <100% indicates contraction and a ves-
sel area >100% indicates relaxation. To compare relaxation
of pre-treated vessels, the vessel area was defined after pre-
treatment again as 100%. Concentration-response curves
of the vasodilators were performed and the effects reported
as “Change [% of IVA]”. In the graphs, all pre-treatments
were indicated. The luminal area of PVs was monitored
with a digital video camera (Leica Viscam 1280, Leica DFC
280). The images were analyzed with Optimas 6.5 (Media
Cybernetics, Bothell, WA).
Isolated perfused lungs of the GP
Cavine lungs were prepared as described [9, 38]. Briefly,
intraperitoneal anesthesia was performed (pentobarbital:
95 mg kg−1) and verified by missing reflexes. The GP
was bled, the trachea cannulated and the lung ventilated
with positive pressure (70 breaths/min). The left ventricle’s
Fig. 1 Vascular effects of imatinib and ET-1 in pulmonary veins of GPs. a Concentration-response curve of imatinib in naïve PVs: (□) PV (n = 5).
b Treatment of naïve PVs with 1 nM ET-1 to obtain a stable pre-constriction: (■) PV 1 nM ET-1 (n = 6). The dashed line indicates the end of
pre-treatment. c Effect of imatinib in ET-1-pre-constricted PVs: (■) PV (n = 9)
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apex was cut and cannulas were placed in the pulmonary
artery (perfusion inflow) and in the left atrium (perfusion
outflow). The lung was perfused at constant flow
(12,5 mL/min) with Krebs-Henseleit buffer, containing 2%
bovine serum albumin, 0.1% glucose, 0.3% HEPES and 50
nM salbutamol to prevent bronchoconstriction [39]. The
temperature of the perfusate was maintained at 37 °C with
a water bath and the pH was maintained between 7.35
and 7.45 by gassing with carbon dioxide. Heart and lungs
were removed and transferred into a negative-pressure
chamber. Tidal volume, compliance, resistance, pulmonal
arterial pressure (PPA), left atrial pressure (PLA), and the
flow were continuously monitored. As soon as the respira-
tory and hemodynamic variables remained stable over
10 min, ET-1 (20 nM) was added to the recirculating per-
fusion buffer (total volume 200 mL) to enhance Rpost [40].
Ten minutes after the application of ET-1, imatinib
(10 μM) was perfused. At a buffer volume of 200 mL, this
corresponds to total amount of 1.18 mg imatinib or to
3.5 mg/kg body weight imatinib, respectively. Thereafter,
changes of the capillary pressure (Pcap) were measured
every 10 min by the double occlusion method [38],
Rpost and the precapillary resistance (Rpre) were calcu-
lated by the following equations: Rpost ¼ Pcap−PLAFlow and
Rpre ¼ PPA−PcapFlow .
In order to examine the effects of nebulized imatinib
on Rpost, isolated perfused GP lungs were perfused as
described before. After the increase of Rpost by ET-1
(20 nM), 3 mL of imatinib (10 mM), corresponding to
a total amount of 17,691 mg imatinib were nebulized
over a period of 130 min. Assuming a lung flow of 0,21 L/
min (70 breaths à 3 mL) and a pressure of 1.5 bar, the total
amount of inhaled imatinib corresponds to less than 4% of
the nebulized amount of imatinib [41], namely 0,71 mg,
corresponding to 2 mg/kg body weight imatinib, respect-
ively. The contractile effect of ET-1 agonists strongly var-
ies. Therefore, the maximal ET-1-induced increase of Rpost
was normalized to 100% and all submaximal increases of
Rpost were indicated in % of the maximal increase of Rpost.
Chemicals
Imatinib was provided by Novartis (Basel, Switzerland);
nebulized imatinib was solved in aqua at a concentration
of 10 mM. SQ22536, KT5720, KT5823, glibenclamide,
iberiotoxin, 4-aminopyridine and DMPQ were purchased
from Tocris Bioscience (Ellisville, Missouri, USA). ET-1
was acquired from BIOTRENDS (Wangen, Switzerland)
and SU6668 and ponatinib were acquired from Biomol
(Hamburg, Germany). L-Name or standard laboratory
chemicals were obtained from Sigma-Aldrich (Steinheim,
Germany). The ELISA-kits were acquired from Enzo
(Lörrach, Germany). Human PDGF-BB was delivered by
Peprotech (Hamburg, Germany).
Statistical analysis
Statistics were conducted using SAS software 9.3 (SAS
Institute, Cary, North Carolina, USA) and GraphPad Prism
5.01 (GraphPad, La Jolla, USA). The data in Figs. 4, 5 and
6a,b,e,f were analyzed using a linear mixed model analysis
(LMM) with the covariance structures VC or AR(1); EC50
values (Figs. 2b, c, e, f, 3b and 6c, d) were calculated by
the standard 4-parameter logistic non-linear regression
model (GraphPad, La Jolla, USA). The AIC-criterion was
used to select the most parsimonious model, i.e. a com-
mon top, bottom, slope and EC50 value in the regression
model or the covariance matrix with the least number of
parameters. Non-parametric analysis (Figs. 2a, d and 3a, c)
was performed by the Mann–Whitney U test. All p-values
were adjusted for multiple comparisons by the false discov-
ery rate and are presented as mean ± SEM; n indicates the
numbers of animals. P <0.05 was considered as significant.
Results
We studied the relaxant effects of imatinib in naïve (not
pre-constricted) and in pre-constricted PVs.
ET-1-induced pre-constriction and imatinib-induced
relaxation
Imatinib did not relax naïve PVs from GPs (Fig. 1a). To
obtain a stable and comparable contraction PVs were pre-
constricted with ET-1 (1 nM). After 1 h, ET-1 (1 nM)
contracted PVs to 69% of IVA (Fig. 1b), and imatinib
(100 μM) relaxed PVs to 126% of IVA (Fig. 1c).
Involvement of the cAMP/PKA-pathway to the vasorelaxant
effect of imatinib
In PVs, imatinib increased intracellular cAMP (Fig. 2a).
The functional role of the cAMP/PKA-pathway was
addressed by pre-treatments with the adenyl cyclase-
inhibitor SQ22536 (100 μM) and the PKA-inhibitor
KT5720 (1 μM). Both inhibitors alone do not alter the
contractile effect of ET-1 [29], but here they decreased
the imatinib-induced relaxation (Fig. 2b, c). To study
the contribution of NO or NO-downstream products
(cGMP/PKG) to the imatinib-induced relaxation, PVs were
pre-treated with the NO-synthase-inhibitor L-NAME
(100 μM) or the PKG-inhibitor KT5823 (2 μM). Both
inhibitors do not affect the ET-1-induced contraction
[29]. Here, L-NAME and KT5823 did also not alter the
relaxant effect of imatinib (Fig. 2e, f). Accordingly, imatinib
did not increase intracellular cGMP-levels in PVs (Fig. 2d).
Involvement of K+-channels to the vasorelaxant effect of
imatinib
We further evaluated the impact of K+-channel-activation
in the imatinib-induced relaxation of cavine PVs.
KATP -channel-inhibition by glibenclamide (10 μM),
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BKCa2þ -channel-inhibition by iberiotoxin (100 nM)
and Kv -channel-inhibition by 5 mM 4-aminopyridine
(4-AP) do not affect ET-1-induced contraction [29].
However, inhibition of KATP -channels, BKCa2þ -channels
or Kv-channels significantly reduced the relaxant effect of
imatinib (Fig. 3a-c); inhibition of KATP - or Kv -channels
was most effective.
Imatinib lowers the Rpost in the IPL
To elucidate whether and how imatinib affects the pul-
monary venous bed in an intact organ, we perfused and
nebulized imatinib in the IPL after raising Rpost by ET-
1. In the IPL, perfusion of 20 nM ET-1 increased PPA
about 600% of baseline from 1.5 cmH2O to 9.5 cmH2O
(p <0.0001), whereas control lungs had no increase of
PPA and remained stable (Fig. 4a). ET-1 did not affect
PLA (Fig. 4b). Further, the experiments with the double
occlusion method revealed that ET-1 significantly en-
hanced Rpre up to 312% and Rpost up to 169% of base-
line (Fig. 4c, d). Next we studied if perfused or nebulized
imatinib significantly affects Rpost. Perfusion of imatinib
significantly lowered the ET-1-induced increase of Rpost
(Fig. 5a), even though Rpost was still increased (p <0.05)
compared to control lungs (Fig. 5a). Nebulization of ima-
tinib (calculated dosage: 2 mg/kg body weight) reduced
the ET-1-induced increase of Rpost from the time points
110 – 150 min, but Rpost was still significantly increased
(p <0.001) compared to control lungs (Fig. 5b).
The role of PDGFR-β and interaction of ET-1 with PDGFR
The antiproliferative properties of imatinib are likely
explained by PDGFR-inhibition. Thus, we hypothesized
that the imatinib-induced relaxation may depend on in-
hibition of PDGFR kinase activity and further that PDGF-
BB may possibly exert contractile properties in pulmonary
vessels. To test this hypothesis and to identify, which
PDGFR-subunit might be responsible for a possible con-
tractile effect, we pre-treated PVs with 100 μM imatinib
(PDGFR), 5 μM SU6668 (PDGFR-β) or 100 nM ponatinib
(PDGFR-α) prior to the treatment with 10 or 100 nM
PDGF-BB. Control PVs treated with 10 or 100 nM PDGF-
BB contracted up to 70% of IVA. In contrast, pre-treatment
Fig. 2 Role of cAMP/cGMP in imatinib-induced relaxation of GP pulmonary veins. a Effect of imatinib on intracellular cAMP. b Effect of inhibition
of adenyl cyclase (SQ22536) on imatinib-induced relaxation in ET-1 (1 nM) pre-constricted PVs: (■) imatinib (n = 9); ( ) SQ22536 (100 μM), imatinib
(n = 7); (□) SQ22526 (100 μM) (n = 6). c Effect of inhibition of PKA (KT5720) on imatinib-induced relaxation in ET-1 (1 nM) pre-constricted PVs: (■)
imatinib (n = 9); ( ) KT5720 (1 μM), imatinib (n = 7); (□) KT5720 (1 μM) (n = 6). d Effect of imatinib on cGMP. e Effect of inhibition of NO-synthase
(L-NAME) on imatinib-induced relaxation in ET-1 (1 nM) pre-constricted PVs: (■) imatinib (n = 9); ( ) L-NAME (100 μM), imatinib (n = 8); (□)
L-NAME (100 μM) (n = 5). f Effect of inhibition of PKG (KT5823) on imatinib-induced relaxation in ET-1 (1 nM) pre-constricted PVs: (■) imatinib (n = 9);
( ) KT5823 (2 μM), imatinib (n = 11); (□) KT5823 (2 μM) (n = 6). A/D) Statistics was performed by the Mann–Whitney U test. b/c/e/f) Asterisks indicate
different EC50 values. P <0.05 are considered as significant: * p <0.05, ** p <0.01 and *** p <0.001
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with imatinib and SU6668 abolished the contractile effect
of PDGF-BB, whereas pre-treatment with ponatinib only
insignificantly reduced the contractile effect of PDGF-BB
(Fig. 6a, b). Next, we analyzed the effects of the PDGFR-α
inhibitor ponatinib and the PDGFR-β inhibitors SU6668
and DMPQ on PVs pre-constricted with ET-1. Treatment
with SU6668 and DMPQ relaxed PVs pre-constricted with
ET-1 up to 140% of IVA (Fig. 6c), whereas treatment with
the PDGFR-α inhibitor ponatinib had no significant
relaxant effect (Fig. 6c). Further, concomitant pre-treatment
with 5 μM SU6668 and 1 nM ET-1 or 5 μM DMPQ and 1
nM ET-1 (Fig. 6d) abolished imatinib-induced relaxation,
exceptional if it was applied at 100 μM. Next, we studied
whether stimulation of ET-1 receptors interacts any-
how with PDGFR or conversely, if activation of
PDGFR contributes to the contractile effect of ET-1.
In order to inhibit PDGFR, we pre-treated PVs 60 min
with imatinib (10 or 100 μM), 5 μM SU6668 or 100
nM ponatinib prior to the treatment of 1 nM ET-1
(Fig. 6e, f ). We found, irrespective of inhibition of
PDGFR-αβ, ET-1 contracted PVs without significant
difference (Fig. 6e, f ).
Discussion
The tyrosine kinase inhibitor imatinib represents an
intriguing approach to treat PH. Initially, research fo-
cused on the antiproliferative effects of imatinib, in
line with the reversal of vascular remodeling in experi-
mental studies [42]. Interestingly, in clinical trials and
case reports, imatinib also ameliorated hemodynamics
[11, 12, 16] and restored heart function [13] suggesting
that it may also improve vascular tone. Meanwhile,
corroborating studies in PAs from healthy or hyperten-
sive rats demonstrated the relaxant effects of imatinib
[14, 15]. Clinically, however, effects on PVs may be
more relevant since the most common cause of PH is
LHD, a condition that primarily affects PVs [8, 43].
Therefore, in the present study we focused on the relaxant
effects of imatinib in the pulmonary venous bed. We se-
lected GPs, as the access to human lung tissue is limited
and the pulmonary smooth muscle pharmacology of GPs
resembles human tissue much better than rats or mice
[28, 44]. Most studies were performed using PCLS, a
method [28, 29] that allows to study PVs within their nat-
ural tissue anatomy [45]. To study the effects of imatinib
Fig. 3 Contribution of K+-channels to imatinib-induced relaxation of GP pulmonary veins. a Effect of inhibition of KATP-channels (glibenclamide)
on imatinib-induced relaxation in ET-1 (1 nM) pre-constricted PVs: (■) imatinib (n = 9); ( ) glibenclamide (10 μM), imatinib (n = 8); (□) glibenclamide
(10 μM) (n= 8); b Effect of inhibition of BKCa2þ-channels (iberiotoxin) on imatinib-induced relaxation in ET-1 (1 nM) pre-constricted PVs: (■)
imatinib (n = 9); ( ) iberiotoxin (100 nM), imatinib (n = 8); (□) iberiotoxin (100 nM) (n = 8); c Effect of inhibition of Kv-channels (5-aminopyridine)
on imatinib-induced relaxation in ET-1 (1 nM) pre-constricted PVs: (■) imatinib (n = 9); ( ) 4-AP (5 mM), imatinib (n = 10); (□) 4-AP (5 mM) (n = 10).
a/c Corresponding concentrations of (■) and ( ) were compared by the Mann–Whitney U test. b Asterisks indicate different EC50 values. P <0.05 are
considered as significant: * p <0.05 and ** p <0.01
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Fig. 4 Influence of ET-1 on different segments of the pulmonary circulation in the IPL. a Influence of 20 nM ET-1 on the pulmonary arterial pressure
(PPA): (○) control (n = 6); (●) ET-1 20 nM (n = 7); b Influence of 20 nM ET-1 on the left atrial pressure (PLA): (○) control (n = 6); (●) ET-1 20 nM
(n = 7); c Influence of 20 nM ET-1 on the precapillary resistance (Rpre): (○) control (n = 6); (●) ET-1 20 nM (n = 7); d Influence of 20 nM ET-1 on
the postcapillary resistance (Rpost): (○) control (n = 6); (●) ET-1 20 nM (n = 7). a-d) Statistics was performed by a LMM. P <0.05 are considered
as significant: * p <0.05, ** p <0.01 and *** p <0.001
Fig. 5 Influence of perfused and nebulized imatinib on the ET-1-induced increase of Rpost. a Influence of perfused imatinib on the ET-1-induced
increase of the postcapillary resistance (Rpost): (○) control (n = 6); (●) ET-1 20 nM (n = 7); ( ) ET-1 20 nM / imatinib 20 mM (n = 6). b Influence of
nebulized imatinib on the ET-1-induced increase of the postcapillary resistance (Rpost): (○) control (n = 6); (●) ET-1 20 nM (n = 7); ( ) ET-1 20 nM/
imatinib 20 mM (n = 7). a-b Statistics was performed by a LMM. P <0.05 are considered as significant: * p <0.05 and *** p <0.001
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on the Rpost, we used the double occlusion method [38] in
isolated perfused lungs (IPL) of GPs. To mimic a patho-
physiological aspect of PH, namely the overexpression of
ET-1 and its receptor [46, 47], we pre-constricted PVs
with ET-1.
In the present study, imatinib relaxed pre-constricted
PVs with an EC50 value of 32 μM in line with a previous
study in PAs [14]. Imatinib-induced relaxation was
dependent on the generation of cAMP and on the acti-
vation of K+-channels. In the IPL, perfused or nebulized
Fig. 6 The role of PDGFR-β and interaction of ET-1 with PDGFR. a Effect of inhibition of PDGFR (imatinib) on the contractile effect of 10 nM
PDGF-BB: (■) PV: PDGF-BB (10 nM) (n = 5); (□) PV: imatinib (100 μM), PDGF-BB (n = 5). b Effect of inhibition of PDGFR-α (ponatinib) and PDGFR-β
(SU6668) on the contractile effect of PDGF-BB: (■) PV: PDGF-BB (100 nM) (n = 7); (□) PV: SU6668 (5 μM), PDGF-BB (100 nM) (n = 6); ( ) PV: Ponatinib
(100 nM), PDGF-BB (100 nM) (n = 7). c The relaxant effects of the unselective TKI imatinib and the PDGFR-β inhibitors SU6668 or DMPQ in ET-1
pre-constricted PVs: (■) PV 1 nM ET-1/imatinib (n = 5); ( ) PV: 1 nM ET-1/SU6668 (n = 5); (□) PV: 1 nM ET-1/DMPQ (n = 5); (●) PV: 1 nM ET-1/ponatinib
(n = 5); d The relaxant effect of the unselective TKI imatinib after inhibition of PDGFR-β by SU6668 or DMPQ: (■) PV: 5 μM SU6668/1 nM ET-1/imatinib;
(□) PV: 5 μM DMPQ/1 nM ET-1/imatinib; e/f Effect of inhibition of PDGFR (imatinib), PDGFR-α (ponatinib) and PDGFR-β (SU6668) on ET-1 induced
contraction: (■) PV: ET-1 (1 nM) (n = 5); ( ) PV: 100 μM imatinib/1 nM ET-1 (n = 5); ( ) PV: 1 μM imatinib/1 nM ET-1 (n = 5); ( ) PV: 5 μM SU6668/1 nM
ET-1 (n = 5); ( ) PV: 100 nM ponatinib/1 nM ET-1 (n = 5). Statistics was performed by LMM (Fig. 6a, b, e, f). Asterics indicate different EC50 values
(Fig. 6c, d). P <0.05 are considered as significant: *** < 0.001
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imatinib reduced the ET-1-induced increase of Rpost.
Notably, nebulized imatinib might prevent perfusion/
ventilation mismatches and imatinib-related systemic
side effects such as subdural hematoma or hypotension.
Further, PDGF-BB contracts PVs, a finding which might
explain in part why imatinib exerts relaxation. Our re-
sults suggest the use of imatinib in the therapy of PH
due to LHD.
Mechanisms contributing to imatinib-induced relaxation
The tone of vascular SMCs is regulated by various sig-
naling cascades, which ultimately modulate intracellular
Ca2+-levels or/and Ca2+-sensitivity of the myofilaments.
In this context, the nucleotides cAMP and cGMP play a
leading part. Cyclic AMP — via activation of PKA —
causes relaxation by K+-channel-stimulation. Further,
cAMP acts in a Ca2+-desensitizing manner: 1) cAMP
blocks myosin light chain kinase (MLCK); 2) cAMP acti-
vates myosin light chain phosphatase (MLCP) [48]. It
has been reported that Ca2+-desensitization plays a
role in imatinib-induced relaxation [14]. Here we show
that imatinib leads to increased intracellular cAMP
levels in cavine PVs. The functional relevance of this
cAMP-increase was shown by inhibiting adenyl cy-
clase (SQ22536) or PKA (KT5720); both inhibitors
attenuated the relaxant effect of imatinib. The gener-
ation of cAMP has not yet been reported within the
context of imatinib- or TKI-induced vasorelaxation,
even though they are supported by own unpublished
results from human pulmonary vessels and by Kim et al.
[49] who proved in murine interstitial cell of Cajals that
the imatinib-induced inhibition of pacemaker potentials
depends on the generation of cAMP [49]. These results
raise the question, how to explain the imatinib-induced in-
crease of cAMP or more precisely how PDGFR-inhibition
is linked to the activation of Gαs, the inhibition of Gαi or
the inhibition of PDE-III: 1) There is evidence that RTKs
and GPCR interact together, e.g. via transactivation [50],
as it was already shown for EGF and Gαi [51]. 2) Recently
it was reported that PDGF inhibits regulators of G protein
signaling (RGS) [52]. In particular, it was shown that
PDGF suppresses the expression of RGS-5 in vascular
SMC; since downregulation of RGS-5 activates Gαi, adenyl
cyclase is blocked and the generation of intracellular
cAMP reduced.
Cyclic AMP/PKA-signaling appears critical for the
imatinib-induced relaxation, although inhibition of adenyl
cyclase or PKA did not completely prevent it. This sug-
gests the involvement of other signaling cascades such as
NO/cGMP/PKG. PKG promotes Ca2+-desensitization
via MLCP-activation and stimulates K+-channels [48].
The NO/cGMP/PKG-signaling highly depends on an
intact endothelium releasing aside NO [53] also prosta-
cyclin [54, 55]. In PCLS, PVs dispose of an intact
endothelium [56], even though NO/cGMP/PKG-signaling
did not contribute to imatinib-induced relaxation, as 1)
imatinib failed to increase cGMP; 2) inhibition of NO-
synthesis (L-NAME) or PKG (KT5823) did not attenuate
imatinib-induced relaxation. Despite these results, we
cannot conclude if imatinib-induced relaxation is endo-
thelium independent or dependent, as it is highly based
on cAMP/PKA-signaling and within this context, the
endothelial release of prostacyclin might be of impact.
Our results corroborate in part those of Abe et al. [14],
who showed that imatinib relaxes PAs from hypertensive
rats, despite NO-inhibition. Aside that, they [14] proved in
endothelial denuded PAs (rats) that the relaxant effect of
imatinib does not depend on the endothelium or the
endothelial prostacyclin release, as well. In contrast, in
SMCs from human corpus cavernosum [57] and in pros-
tatic SMCs [58], imatinib-induced relaxation appears to
depend on NO-signaling. Thus, the role of NO/PKG/
cGMP in the imatinib-induced relaxation appears to be
species and organ-specific.
To study further mechanisms, we evaluated the im-
pact of KATP-, BKCa2þ - and Kv-channels, all of which
are expressed in pulmonary vessels [59, 60]. Activation
of K+-channels leads to cell membrane hyperpolariza-
tion resulting in reduced cytosolic Ca2+-influx and in
relaxation of vascular SMCs. In GP PVs, inhibition of
all three K+-channels attenuated imatinib-induced re-
laxation, with KATP- and Kv-channel inhibitors being
more effective. The minor role of BKCa2þ -channels
might be explained by the fact that BKCa2þ -channels
dominate in conduit PAs [59], although in rat PAs
K+-channel-activation could not explain the imatinib-
induced relaxation [15]. In line with our results, a dominant
role of KATP- versus BKCa2þ -channels was demonstrated
for the imatinib-induced relaxation in human prostatic
SMCs [58]. Conversely, PDGF has been shown to decrease
Kv-channel currents [61]. Moreover, the imatinib-induced
activation of K+-channels does not only mediate relaxation,
but also contributes to its antiproliferative effects, as hyper-
polarization of the cell membrane lowers the intracellu-
lar Ca2+-influx/content and counteracts the vascular
remodeling [59]. A similar relationship has also been
shown for the Ca2+-sensitizer levosimendan that de-
velops pulmonary vasorelaxant effects [29] and anti-
proliferative properties via K+-channel-activation [62].
Finally, imatinib-induced relaxation is based on cAMP/
PKA dependent mechanisms and on K+-channel activa-
tion. Both signaling pathways may interact to some
extent in an additive manner [48, 63].
Pulmonary vasorelaxant effects of perfused and
nebulized Imatinib in the IPL
The resistance of the pulmonary venous bed, precisely
the postcapillary resistance (Rpost) is increased in PH due
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to LHD and mainly responsible for the generation of
hydrostatic edema [6]. Vice versa, reduction of Rpost is
one of the major therapeutic goals in this disease. To ad-
dress the vasorelaxant effects of imatinib on Rpost in situ,
we perfused imatinib in isolated lungs. This set-up en-
ables: 1) to address the pulmonary arterial and venous
segment independent from each other; 2) to monitor
PPA, PLA and the capillary pressure (Pcap) and 3) to cal-
culate Rpost from PLA and Pcap. In order to access the re-
sistance of the pulmonary venous bed, the calculation of
Rpost is highly relevant, because it includes the small
PVs. Further, it is superior to the Ppcw, which rather re-
flects the pressure in large PVs [64] or PLA [65].
Perfusion of 20 nM ET-1 significantly increased PPA,
Rpre and Rpost in the IPL. In contrast, PLA did not
change, as it is expected due to the reservoir function of
the left atrium in this model. In the present study, perfu-
sion of 10 μM imatinib significantly lowered Rpost. This
finding is in line with the results of the IMPRES study
that showed improved hemodynamics after the applica-
tion of imatinib, expressed as a decrease in PVR and an
increase in the 6 min walk distance [16]; of note, the
IMPRES study only included patients with PAH [16].
Our results are further supported by Shah et al. [13],
who found that imatinib improves right but also left
heart function. However, the IMPRES study [16], as well
as the long-term extension of the IMPRES study [17]
further revealed undesirable imatinib-related side effects
such as vomiting, nausea or peripheral edema that de-
crease patient compliance; and even more critical were
the occurrence of subdural hematoma, QTc prolonga-
tion, cardiac failure and syncope, the latter two most
probably being caused by systemic hypotension [16, 17].
Unfortunately, however in PH, systemic hypotension is
quite problematic, as it decreases the coronary perfusion
pressure and consequently worsens left and right ven-
tricular function [66]. To find a way to prevent systemic
side effects, we evaluated the possibility and efficacy to
apply imatinib locally via the airways [18], as it is already
usual in PH for NO-donors, prostanoids or PDE-inhibitors
[67, 68]. In the IPL, we could show that nebulized imatinib
reduces the ET-1-induced increase of Rpost. The results
from the IPL (perfusion/nebulization) correspond to our
data from PCLS, even though nebulization of imatinib was
less effective in reducing Rpost than perfusion. As men-
tioned above (methods), these differences are probably
explained by the maximal imatinib up-take: the ima-
tinib up-take via nebulization is 0.71 mg corresponding
to 2 mg/kg body weight imatinib and via perfusion
1.18 mg corresponding to 3.5 mg/kg body weight ima-
tinib (the ratio is 0.6). Other effects may also play a role
such as an insufficient imatinib-uptake through the
alveo-capillary membrane or the degradation of imatinib
by intraalveolar macrophages. Here, we performed an
IPL model; thus the extent to which nebulized imatinib
provokes systemic adverse effects remains to be shown.
In summary, we focused on central PVs in PCLS and
we addressed Rpost (IPL), resembling the peripheral part
of the pulmonary venous bed [69, 70]. In both models,
we demonstrated that imatinib relaxes the pulmonary
venous bed of GPs.
The role of PDGFR-β and interaction of ET-1 with PDGFR
The antiproliferative effects of imatinib are attributed
to inhibition of the tyrosine kinase activity of PDGFR [20].
Beyond that, PDGFR activation is known to enhance the
tone of various vessel types from different species by
the increase of intracellular Ca2+ [26, 71]. So far it is
unknown, if imatinib-induced relaxation is linked to
PDGFR-inhibition, and further if PDGF also contracts
pulmonary vessels. Here, we showed that PDGF-BB
contracts PVs and that this contraction is completely
prevented by the unselective PDGFR-αβ-inhibitor ima-
tinib. PDGFR-β-inhibition (SU6668) abolished PDGF-BB-
induced contraction, whereas PDGFR-α-inhibition
(ponatinib) reduced it only mildly and non-significantly.
In general, PDGF-BB binds to PDGFR-αα, αβ or ββ [23].
Hence, our results suggest 1) a leading role of PDGFR-ββ
or/and PDGFR-αβ, as inhibition of the β-subunit com-
pletely prevented PDGF-BB-induced contraction and 2) a
minor role of PDGFR-αα, as inhibition of the α-subunit
did not prevent contraction. SU6668 has multiple targets
such as Aurora kinases, TBK1 and the RTK VEGFR-2,
FGFR-1, EGFR or FLK-1/KDR [35]. SU6668 (5 μM)
blocks VEGFR-2 (IC50 0.34–2.43 μM) and FGFR-1
(IC50 1.2–10 μM) only moderately, whereas ponatinib
(100 nM) potently blocks VEGFR-2 (IC50 1.5 nM) and
FGFR-1 (IC50 2.2 nM). Hence, if the inhibition of VEGFR-
2 or FGFR-2 would prevent the PDGF-BB-induced con-
traction, ponatinib should be more effective than SU6668.
In addition, the complete inhibition of EGFR (IC50 >100
nM) or FLK-1/KDR (IC50 2.1 μM) would require SU6668
concentrations above 5 μM. These considerations support
the idea that the contractile effect of PDGF-BB is pre-
vented by inhibition of PDGFR-β [32–37, 72–75]. Con-
versely, the PDGFR-β inhibitors SU6668 and DMPQ
relaxed pre-constricted PVs, whereas the PDGFR-α inhibi-
tor ponatinib had no effect. Further, after inhibition of
PDGFR-β by SU6668 or DMPQ (both 5 μM), imatinib
only relaxed pre-constricted PVs at 100 μM. These data
suggests that imatinib-induced relaxation depends on
PDGFR-β inhibition. Thus, our findings suggest that
PDGFR-β antagonism does not only attenuate the es-
tablishment of PH [10, 76], but also mediates vasorelax-
ation. Our results are supported by Shiba et al. [77]
who proved in cerebral arteries that imatinib counter-
acts PDGFR-signaling and prevents vasospasm. In an
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effort to identify a link between ET-1- and PDGFR sig-
naling, we studied if activated ET-1 receptors interact
anyhow with PDGFR. To this end, we inhibited PDGFR
prior to the treatment with ET-1. Neither inhibition of
PDGFR (imatinib), PDGFR-β (SU6668) nor PDGFR-α
(ponatinib) did reduce ET-1-induced contraction. Hence,
it appears that stimulation of ET-1 receptors does not acti-
vate PDGFR or it takes place, but without being sufficient
to mediate contraction, possibly because ligand-binding is
missing. Recently, Harada and coworkers [78] could show
in rat L6 myoblasts that stimulation of ET-1 receptors ac-
tivates PDGFR downstream signaling by an unknown
mechanism. However, they did not study ET-1-induced
phosphorylation of PDGFR [78].
Irrespective from a possible interaction of ET-1 and
PDGFR, the relaxant effect of imatinib is not limited to
ET-1, as it relaxed PAs pre-constricted with U46619 [14,
15], serotonin [14] or L-NAME [15]. Further, imatinib ex-
erts relaxant effects in different tissues, i.e. systemic vessels
[15], prostatic tissue [58], PAs [14, 15], corpus cavernosum
[57], myometrium [79] and stomach [80] from humans,
rabbits, GPs, rats or sheep. Thus, imatinib-induced relax-
ation appears to be a widespread phenomenon. Beyond
that, other TKIs also exert pulmonary vascular relaxant
effects (nilotinib/sorafenib) [14] or prevent experimental
pulmonary vascular remodeling by PDGFR-inhibition
(nilotinib/dasatinib). Within this context, dasatinib plays a
particular role, as it also inhibits Src kinases playing a piv-
otal role in pulmonary arterial remodeling [81, 82]. That is
probably why; dasatinib reverses experimental PH even
more potently than imatinib [81]. However in patients with
CML, dasatinib also provoke drug-induced PAH by an
unknown mechanism [83, 84]. Fortunately, this dasatinib-
associated adverse effect appears to be reversible, rare
and limited to dasatinib [85–88].
Conclusions
Imatinib relaxes PVs by activation of cAMP/PKA and
potassium channels (KATP-, BKCa2þ-, Kv-channels), mecha-
nisms that are related in an unknown way to the inhibition
of PDGFR-β. The clinical importance of imatinib-induced
relaxation is supported by reports that imatinib improved
the clinical condition of a patient with pulmonary venous
occlusive disease within 24 h [12] and ameliorated PH due
to congenital hernia [11]. The prompt improvement in both
cases favors relaxant effects of imatinib in contrast to the
reversal of vascular remodeling which lasts longer [10].
However, until now studies with human pulmonary vessels
are still missing and quite difficult to obtain. Our data
suggest a beneficial role of imatinib in PH due to LHD.
Since imatinib combines short-term relaxant, even if
inhaled and long-term antiproliferative effects, it may
represent a promising approach to treat PH due to LHD.
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